Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism, Excretion, and Mass Balance of [14C]-Quemliclustat in Healthy Adult Males
NCT07364214Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quemliclustat, sponsored by Arcus Biosciences. Primary endpoints: Percentage of total radioactivity excreted in urine and feces up to 40 days, Total radioactivity in blood up to 40 days and 3 more. Started Feb 2026; status: completed.
02
Drugs
quemliclustat
Beyond the preview
Go deeper on NCT07364214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364214.